We are developing the first AI-derived mRNA nanoparticle vaccines with advanced deep learning AI models. Our mRNA vaccines directly encoding for highly immunogenic nanoparticles provide a flexible platform directly applicable to zoonotic viruses that constitute a rising threat worldwide.
Our SARS-CoV-2 vaccine is designed to complement the limited immunity provided by current and previous COVID vaccines, and to protect against the latest variants prevalent worldwide. Our SARS-CoV-2 vaccine is also designed to counter immune imprinting which limits the efficacy of all COVID vaccines to date.
Our Nipah virus vaccine is the first mRNA nanoparticle vaccine against the Nipah virus causing the recent outbreaks in India and South Asia with very high fatality rates.
We are also developing AI-derived mRNA nanoparticle vaccines against the Chikungunya virus and the West Nile virus that are emerging threats in Europe and North America.
A critical advantage of our mRNA nanoparticle vaccines is to induce long-lasting immunity as compared with current mRNA vaccines. They are also designed to protect against neurological symptoms caused by viral dissemination, such as long COVID syndrome and Nipah or West Nile encephalitis.